Emmaus Life Sciences annual ebitda
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Emmaus Life Sciences's calculated EBITDA was $270,000 for fiscal 2025.
View full Emmaus Life Sciences company overview| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $270,000 | $2.1M | — |
| 2024 | 2024-12-31 | −$1.9M | −$5.4M | — |
| 2023 | 2023-12-31 | $3.6M | $10.1M | — |
| 2022 | 2022-12-31 | −$6.5M | −$464,000 | — |
| 2021 | 2021-12-31 | −$6.1M | −$6.1M | — |
| 2020 | 2020-12-31 | $28,000 | $4.5M | — |
| 2019 | 2019-12-31 | −$4.4M | $5.7M | — |
| 2018 | 2018-09-30 | −$10.1M | −$3.1M | — |
| 2017 | 2017-09-30 | −$7.1M | −$3.3M | — |
| 2016 | 2016-09-30 | −$3.8M | −$1.1M | — |
| 2015 | 2015-09-30 | −$2.6M | $1.2M | — |
| 2014 | 2014-09-30 | −$3.8M | — | — |
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.8M | $4.2M | — |
| Q1 2026 | 2026-03-31 | −$808,000 | $167,000 | — |
| Q4 2025 | 2025-12-31 | $901,000 | $1.5M | — |
| Q3 2025 | 2025-09-30 | $710,000 | −$116,000 | −14.04% |
| Q2 2025 | 2025-06-30 | −$366,000 | −$954,000 | — |
| Q1 2025 | 2025-03-31 | −$975,000 | $1.8M | — |
| Q4 2024 | 2024-12-31 | −$552,000 | −$1.9M | — |
| Q3 2024 | 2024-09-30 | $826,000 | $794,000 | +2481.25% |
| Q2 2024 | 2024-06-30 | $588,000 | −$2.7M | −82.37% |
| Q1 2024 | 2024-03-31 | −$2.7M | −$1.6M | — |
| Q4 2023 | 2023-12-31 | $1.4M | $2.8M | — |
| Q3 2023 | 2023-09-30 | $32,000 | $680,000 | — |
| Q2 2023 | 2023-06-30 | $3.3M | $4.8M | — |
| Q1 2023 | 2023-03-31 | −$1.2M | $1.9M | — |
| Q4 2022 | 2022-12-31 | −$1.4M | $3.5M | — |
| Q3 2022 | 2022-09-30 | −$648,000 | −$631,000 | — |
| Q2 2022 | 2022-06-30 | −$1.4M | −$1.9M | — |
| Q1 2022 | 2022-03-31 | −$3.1M | −$1.5M | — |
| Q4 2021 | 2021-12-31 | −$5.0M | −$5.3M | — |
| Q3 2021 | 2021-09-30 | −$17,000 | −$40,000 | — |
| Q2 2021 | 2021-06-30 | $498,000 | $2.0M | — |
| Q1 2021 | 2021-03-31 | −$1.6M | −$2.7M | — |
| Q4 2020 | 2020-12-31 | $376,000 | −$343,000 | −47.71% |
| Q3 2020 | 2020-09-30 | $23,000 | $4.1M | — |
| Q2 2020 | 2020-06-30 | −$1.5M | −$1.7M | — |
| Q1 2020 | 2020-03-31 | $1.1M | $2.4M | — |
| Q4 2019 | 2019-12-31 | $719,000 | $3.4M | — |
| Q3 2019 · Sep 30 | 2019-09-30 | −$4.0M | −$2.1M | — |
| Q3 2019 · Jun 30 | 2019-06-30 | $134,000 | $3.0M | — |
| Q2 2019 | 2019-03-31 | −$1.3M | $1.3M | — |
| Q1 2019 | 2018-12-31 | −$2.7M | $81,000 | — |
| Q4 2018 | 2018-09-30 | −$1.9M | $765,100 | — |
| Q3 2018 | 2018-06-30 | −$2.9M | −$1.3M | — |
| Q2 2018 | 2018-03-31 | −$2.6M | −$1.2M | — |
| Q1 2018 | 2017-12-31 | −$2.7M | −$1.3M | — |
| Q4 2017 | 2017-09-30 | −$2.7M | −$1.0M | — |
| Q3 2017 | 2017-06-30 | −$1.5M | −$731,200 | — |
| Q2 2017 | 2017-03-31 | −$1.4M | −$721,200 | — |
| Q1 2017 | 2016-12-31 | −$1.4M | −$804,600 | — |
| Q4 2016 | 2016-09-30 | −$1.6M | −$1.1M | — |
| Q3 2016 | 2016-06-30 | −$808,000 | −$253,600 | — |
| Q2 2016 | 2016-03-31 | −$688,700 | $89,200 | — |
| Q1 2016 | 2015-12-31 | −$623,300 | $153,700 | — |
| Q4 2015 | 2015-09-30 | −$532,900 | — | — |
| Q3 2015 | 2015-06-30 | −$554,400 | — | — |
| Q2 2015 | 2015-03-31 | −$777,900 | — | — |
| Q1 2015 | 2014-12-31 | −$777,000 | — | — |
Over the last five reported fiscal years, Emmaus Life Sciences's ebitda increased from $28,000 to $270,000, a change of $242,000. The latest reported quarter, Q2 2026, shows $3.8M.
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Emmaus Life Sciences filings at SEC.gov ↗